CTI BioPharma (CTIC) – StreetInsider.com Reports
-
SVB MoffettNathanson Downgrades CTI BioPharma (CTIC) to Market Perform
-
JMP Securities Downgrades CTI BioPharma (CTIC) to Market Perform
-
Needham & Company Downgrades CTI BioPharma (CTIC) to Hold
-
Lake Street Capital Markets Downgrades CTI BioPharma (CTIC) to Hold
-
CTI BioPharma (CTIC) Acquired by Sobi for $9.10/sh or $1.7B Cash
-
CTI BioPharma (CTIC) PT Lowered to $8 at TD Cowen
-
Increasing unusual option volume
-
CTI BioPharma (CTIC) PT Lowered to $9 at BTIG
-
CTI BioPharma (CTIC) PT Lowered to $8.10 at Stifel
-
Increasing unusual option volume: CTIC XP LU WWE PRTY BZUN BIOR
-
SinoPac Starts CTI BioPharma (CTIC) at
-
CTI BioPharma (CTIC) Eliminates COO Position
-
CTI BioPharma (CTIC) PT Lowered to $8.70 at Stifel
-
CTI BioPharma (CTIC) PT Raised to $9 at Stifel
-
Jefferies Starts CTI BioPharma (CTIC) at Buy
-
CTI BioPharma (CTIC) awarded $3M, five year Veterans Affairs contract
-
CTI BioPharma (CTIC) Files $200M Mixed Shelf
-
CTI BioPharma (CTIC) PT Raised to $7.90 at Stifel
-
CTI BioPharma (CTIC) PT Raised to $9 at JMP Securities
-
CTI BioPharma (CTIC) Misses Q2 EPS by 2c
-
CTI BioPharma (CTIC) PT Raised to $7.50 at Stifel
-
UPDATE: Cowen Starts CTI BioPharma (CTIC) at Outperform
-
CTI BioPharma (CTIC) Presents Pivotal Data from Pacritinib Program
-
"Continue to Expect Increased Uptake of Vonjo" - Needham & Company Reiterates Buy Rating on CTI BioPharma (CTIC) with $8 Price Target
-
Stifel Reiterates Buy Rating on CTI BioPharma (CTIC) with $6.20 Price Target
-
Needham & Company Reiterates Buy Rating, $8 Price Target on CTI BioPharma (CTIC) Following Q1 Report, "We Are Encouraged by Initial Strong Numbers"
-
CTI BioPharma (CTIC) Misses Q1 EPS by 4c
-
CTI BioPharma (CTIC) PT Raised to $6.20 at Stifel
-
CTI BioPharma (CTIC) PT Raised to $6 at JMP Securities
-
Brookline Capital Markets Reiterates Buy Rating. $12 Price Target on CTI BioPharma (CTIC), Notes Recent NCCN Announcement "Support Our Outlook"
-
CTI BioPharma (CTIC) PT Raised to $5.90 at Stifel with a Buy Rating, Analyst Sees Broadening Commercial Opportunity for VONJO
-
CTI BioPharma (CTIC) Announces NCCN Guidelines Recommend VONJO for Treatment of Myeloproliferative Neoplasms
-
CTI BioPharma (CTIC) PT Lowered to $5.40 at Stifel
-
CTI BioPharma (CTIC) PT Raised to $9 at BTIG
-
CTI BioPharma (CTIC) PT Raised to $5 at JMP Securities
-
CTI BioPharma (CTIC) PT Hiked to $8 at Needham & Company, Analyst Sees Commercial Success of VONJO with Peak Sales of $595M
-
CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
-
Increasing unusual option volume: MULN EQNR APLS WEAT CTIC
-
Pre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
-
CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
-
Stifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval
-
CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO
-
CTI BioPharma (CTIC) PT Raised to $7.20 at Brookline Capital Markets
-
Increasing unusual option volume: ARDX CTIC VBIV KRYS CRC EL
-
Pre-Open Stock Movers 12/01: (VBIV) (AMBA) (BOX) Higher; (BTAI) (CTIC) (CRM) Lower (more...)
-
CTI BioPharma (CTIC) PT Lowered to $5 at Needham & Company on PDUFA Delay
-
After-Hours Stock Movers 11/30: (AMBA) (BOX) (ZS) Higher; (CTIC) (CRM) (IMGN) Lower (more...)
-
CTI BioPharma (CTIC) Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia
-
CTI BioPharma (CTIC) Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19
-
CTI BioPharma (CTIC) Appoints Diane Parks to Its Board
Back to CTIC Stock Lookup